Oramed Pharmaceuticals (ORMP) Competitors $2.32 -0.06 (-2.52%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ORMP vs. ETTX, MITO, AMLX, TKNO, CYRX, AKBA, YSB, QURE, ZVRA, and LXEOShould you be buying Oramed Pharmaceuticals stock or one of its competitors? The main competitors of Oramed Pharmaceuticals include Entasis Therapeutics (ETTX), Stealth BioTherapeutics (MITO), Amylyx Pharmaceuticals (AMLX), Alpha Teknova (TKNO), Cryoport (CYRX), Akebia Therapeutics (AKBA), YS Biopharma (YSB), uniQure (QURE), Zevra Therapeutics (ZVRA), and Lexeo Therapeutics (LXEO). Oramed Pharmaceuticals vs. Entasis Therapeutics Stealth BioTherapeutics Amylyx Pharmaceuticals Alpha Teknova Cryoport Akebia Therapeutics YS Biopharma uniQure Zevra Therapeutics Lexeo Therapeutics Entasis Therapeutics (NASDAQ:ETTX) and Oramed Pharmaceuticals (NASDAQ:ORMP) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, valuation, analyst recommendations, community ranking, media sentiment and dividends. Does the MarketBeat Community favor ETTX or ORMP? Oramed Pharmaceuticals received 223 more outperform votes than Entasis Therapeutics when rated by MarketBeat users. Likewise, 74.19% of users gave Oramed Pharmaceuticals an outperform vote while only 64.86% of users gave Entasis Therapeutics an outperform vote. CompanyUnderperformOutperformEntasis TherapeuticsOutperform Votes9664.86% Underperform Votes5235.14% Oramed PharmaceuticalsOutperform Votes31974.19% Underperform Votes11125.81% Which has stronger valuation and earnings, ETTX or ORMP? Oramed Pharmaceuticals has lower revenue, but higher earnings than Entasis Therapeutics. Entasis Therapeutics is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEntasis Therapeutics$7M14.97-$47.14M-$1.12-1.96Oramed Pharmaceuticals$1.34M70.59$5.53M$0.514.55 Do institutionals and insiders believe in ETTX or ORMP? 6.9% of Entasis Therapeutics shares are held by institutional investors. Comparatively, 12.7% of Oramed Pharmaceuticals shares are held by institutional investors. 6.5% of Entasis Therapeutics shares are held by company insiders. Comparatively, 13.7% of Oramed Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Is ETTX or ORMP more profitable? Oramed Pharmaceuticals' return on equity of 2.70% beat Entasis Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Entasis TherapeuticsN/A -145.48% -103.75% Oramed Pharmaceuticals N/A 2.70%2.10% Which has more risk & volatility, ETTX or ORMP? Entasis Therapeutics has a beta of 1.33, indicating that its share price is 33% more volatile than the S&P 500. Comparatively, Oramed Pharmaceuticals has a beta of 1.77, indicating that its share price is 77% more volatile than the S&P 500. Do analysts prefer ETTX or ORMP? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Entasis Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/AOramed Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the media favor ETTX or ORMP? In the previous week, Oramed Pharmaceuticals had 1 more articles in the media than Entasis Therapeutics. MarketBeat recorded 1 mentions for Oramed Pharmaceuticals and 0 mentions for Entasis Therapeutics. Entasis Therapeutics' average media sentiment score of 0.00 equaled Oramed Pharmaceuticals'average media sentiment score. Company Overall Sentiment Entasis Therapeutics Neutral Oramed Pharmaceuticals Neutral SummaryOramed Pharmaceuticals beats Entasis Therapeutics on 12 of the 13 factors compared between the two stocks. Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Get Oramed Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ORMP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ORMP vs. The Competition Export to ExcelMetricOramed PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$94.58M$7.42B$5.50B$8.53BDividend YieldN/A7.96%5.13%4.14%P/E Ratio4.5510.05116.1015.23Price / Sales70.59400.761,496.2597.74Price / CashN/A47.3939.7434.10Price / Book0.575.594.775.07Net Income$5.53M$153.56M$119.06M$225.46M7 Day Performance-1.90%0.13%0.80%0.37%1 Month Performance-2.93%15.23%5.65%3.57%1 Year Performance28.89%41.14%36.75%29.43% Oramed Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ORMPOramed Pharmaceuticals1.7817 of 5 stars$2.32-2.5%N/A+35.7%$94.58M$1.34M4.5510News CoverageETTXEntasis TherapeuticsN/A$2.19flatN/A+0.0%$104.80M$7M-1.9651MITOStealth BioTherapeuticsN/A$0.32flatN/AN/A$23.54M$21.09M-0.6229AMLXAmylyx Pharmaceuticals4.0961 of 5 stars$5.45+2.6%$14.57+167.4%-67.0%$370.63M$298.76M-2.22200Positive NewsTKNOAlpha Teknova1.0115 of 5 stars$6.93+2.1%$5.00-27.8%+267.7%$369.37M$36.68M-7.45240Upcoming EarningsNews CoverageCYRXCryoport2.5126 of 5 stars$7.17+4.1%$12.00+67.4%-24.9%$353.17M$225.61M-1.951,170Upcoming EarningsShort Interest ↑News CoverageAKBAAkebia Therapeutics4.0531 of 5 stars$1.65+3.5%$5.75+249.5%+91.6%$344.79M$174.50M-7.83167Short Interest ↓News CoverageYSBYS Biopharma1.4582 of 5 starsN/A$5.25+∞N/A$344.32M$560.76M0.00773QUREuniQure2.2854 of 5 stars$6.97+6.7%$19.50+179.8%+1.7%$339.44M$15.84M-1.18500Upcoming EarningsZVRAZevra Therapeutics2.9026 of 5 stars$8.01+3.4%$20.83+160.1%+88.8%$335.24M$23.69M-4.7765Upcoming EarningsPositive NewsLXEOLexeo Therapeutics3.2151 of 5 stars$9.90+4.2%$22.14+123.7%N/A$327.29M$650,000.00-0.6858Analyst ForecastNews Coverage Related Companies and Tools Related Companies Entasis Therapeutics Competitors Stealth BioTherapeutics Competitors Amylyx Pharmaceuticals Competitors Alpha Teknova Competitors Cryoport Competitors Akebia Therapeutics Competitors YS Biopharma Competitors uniQure Competitors Zevra Therapeutics Competitors Lexeo Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ORMP) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | Sponsored[Just Released] Jovine's Emergency Briefing insidePeople didn't believe Jovine when he predicted the 2008 financial crisis over a year in advance. But some read...Behind the Markets | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oramed Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oramed Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
